- Home
- ICCC vs MDCX Comparison
ICCC vs MDCX Comparison
Compare ICCC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- MDCX
- Stock Information
- Founded
- ICCC 1982
- MDCX 2008
- Country
- ICCC United States
- MDCX United States
- Employees
- ICCC N/A
- MDCX N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- MDCX
- Sector
- ICCC Health Care
- MDCX
- Exchange
- ICCC Nasdaq
- MDCX Nasdaq
- Market Cap
- ICCC 55.5M
- MDCX 50.8M
- IPO Year
- ICCC 1987
- MDCX N/A
- Fundamental
- Price
- ICCC $6.16
- MDCX $2.36
- Analyst Decision
- ICCC
- MDCX Strong Buy
- Analyst Count
- ICCC 0
- MDCX 2
- Target Price
- ICCC N/A
- MDCX $23.50
- AVG Volume (30 Days)
- ICCC 19.4K
- MDCX 352.6K
- Earning Date
- ICCC 11-13-2025
- MDCX 11-22-2025
- Dividend Yield
- ICCC N/A
- MDCX N/A
- EPS Growth
- ICCC N/A
- MDCX N/A
- EPS
- ICCC 0.20
- MDCX N/A
- Revenue
- ICCC $28,274,756.00
- MDCX N/A
- Revenue This Year
- ICCC N/A
- MDCX N/A
- Revenue Next Year
- ICCC N/A
- MDCX N/A
- P/E Ratio
- ICCC $31.10
- MDCX N/A
- Revenue Growth
- ICCC 21.75
- MDCX N/A
- 52 Week Low
- ICCC $3.38
- MDCX $1.79
- 52 Week High
- ICCC $7.60
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- ICCC 46.17
- MDCX 47.95
- Support Level
- ICCC $6.06
- MDCX $2.30
- Resistance Level
- ICCC $6.75
- MDCX $2.78
- Average True Range (ATR)
- ICCC 0.36
- MDCX 0.19
- MACD
- ICCC -0.04
- MDCX -0.00
- Stochastic Oscillator
- ICCC 15.31
- MDCX 16.00
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.